Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe, Claudia Göttlich, Lena C. Nelke, Johanna Kühnemundt, Thomas Schwarz, Thomas Nerreter, Hermann Einsele, Heike Walles, Gudrun Dandekar, Sarah L. Nietzer, Michael Hudecek
Lars Wallstabe, Claudia Göttlich, Lena C. Nelke, Johanna Kühnemundt, Thomas Schwarz, Thomas Nerreter, Hermann Einsele, Heike Walles, Gudrun Dandekar, Sarah L. Nietzer, Michael Hudecek
View: Text | PDF
Resource and Technical Advance Immunology Oncology

ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models

  • Text
  • PDF
Abstract

Solid tumors impose immunologic and physical barriers to the efficacy of chimeric antigen receptor (CAR) T cell therapy that are not reflected in conventional preclinical testing against singularized tumor cells in 2-dimensional culture. Here, we established microphysiologic three-dimensional (3D) lung and breast cancer models that resemble architectural and phenotypical features of primary tumors and evaluated the antitumor function of receptor tyrosine kinase–like orphan receptor 1–specific (ROR1-specific) CAR T cells. 3D tumors were established from A549 (non–small cell lung cancer) and MDA-MB-231 (triple-negative breast cancer) cell lines on a biological scaffold with intact basement membrane (BM) under static and dynamic culture conditions, which resulted in progressively increasing cell mass and invasive growth phenotype (dynamic > static; MDA-MB-231 > A549). Treatment with ROR1-CAR T cells conferred potent antitumor effects. In dynamic culture, CAR T cells actively entered arterial medium flow and adhered to and infiltrated the tumor mass. ROR1-CAR T cells penetrated deep into tumor tissue and eliminated multiple layers of tumor cells located above and below the BM. The microphysiologic 3D tumor models developed in this study are standardized, scalable test systems that can be used either in conjunction with or in lieu of animal testing to interrogate the antitumor function of CAR T cells and to obtain proof of concept for their safety and efficacy before clinical application.

Authors

Lars Wallstabe, Claudia Göttlich, Lena C. Nelke, Johanna Kühnemundt, Thomas Schwarz, Thomas Nerreter, Hermann Einsele, Heike Walles, Gudrun Dandekar, Sarah L. Nietzer, Michael Hudecek

×

Figure 2

ROR1-CAR T cells induce apoptosis of 3D lung cancer and breast cancer in static culture.

Options: View larger image (or click on image) Download as PowerPoint
ROR1-CAR T cells induce apoptosis of 3D lung cancer and breast cancer in...
(A) Expression of truncated epidermal growth factor receptor (EGFRt) transduction marker on CD8+ ROR1-CAR T cells before functional testing. ΔMFI depicts the difference in geometric mean fluorescence intensity between ROR1-CAR T cells and unmodified control T cells. (B) Quantification of apoptosis induced by ROR1-CAR T cell treatment with increasing CD8+ T cell numbers for 72 hours. Apoptosis was measured with M30 ELISA from supernatants collected at the indicated time points and is presented as fold change compared with the respective control T cell treatment (red line). n = 4. Data are presented as arithmetic mean ± SD, Wilcoxon’s rank-sum test: *P < 0.05. (C) ELISA-based quantification of IFN-γ and IL-2 from supernatants collected at the indicated time points from static tumor models treated with 1 × 106 T cells for 72 hours. Data are presented as arithmetic mean of 3 cell crowns ± SD. n = 1 experiment. (D) Expression of CD25 and CD69 on CD8+ ROR1-CAR T cells and unmodified control T cells at the end of the 72-hour analysis period in the static tumor model. One representative plot of n = 3 experiments is shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts